Evidence map›Paper›PMID 37991694›Full record

ArticleAdvances in therapy2024

A Patient Charter for Chronic Urticaria.

Marcus Maurer, Mónica Albuquerque, Jean-Nicolas Boursiquot, Elaine Dery, Ana Giménez-Arnau, Kiran Godse, Guillermo Guitiérrez, Amin Kanani, Gina Lacuesta, Jessica McCarthy and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Advances in therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 6 countries.

Marcus MaurerInstitute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Mónica AlbuquerqueAssociação Portuguesa de Doentes de Urticária, Oeiras, Portugal.
Jean-Nicolas BoursiquotCHU de Quebec-Université Laval, Quebec City, Canada.
Elaine DeryCanadian Chronic Urticaria Society, Quebec City, Canada.
Ana Giménez-ArnauHospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain.
Kiran GodseFortis Hiranandani Hospital, Mumbai, India.
Guillermo GuitiérrezFUNDAPSO, Cali, Colombia.
Amin KananiUniversity of British Columbia, Vancouver, Canada.
Gina LacuestaDalhousie University, Halifax, Canada.
Jessica McCarthyNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Simon NigenMontreal General Hospital, McGill University, Montreal, Canada.
Tonya WindersGlobal Allergy & Airways Patient Platform, Vienna, Austria. twinders@gaapp.org.
Charité - Universitätsmedizin Berlin · DEDalhousie University · CAEuropean Federation of Allergy and Airways Diseases Patients Associations · BEFortis Hospital · INMcGill University · CANovartis (United States) · USUniversitat Pompeu Fabra · ESUniversité Laval · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic urticaria (CU) is the recurring development of wheals (aka "hives" or "welts"), angioedema, or both for more than 6 weeks. Wheals and angioedema occur with no definite triggers in chronic spontaneous urticaria, and in response to known and definite physical triggers in chronic inducible urticaria. Approximately 1.4% of individuals globally will have CU during their lifetime. The itching and physical discomfort associated with CU have a profound impact on daily activities, sexual function, work or school performance, and sleep, causing significant impairment in a patient's physical and mental quality of life. CU also places a financial burden on patients and healthcare systems. Patients should feel empowered to self-advocate to receive the best care. The voice of the patient in navigating the journey of CU diagnosis and management may improve patient-provider communication, thereby improving diagnosis and outcomes. A collaboration of patients, providers, advocacy organizations, and pharmaceutical representatives have created a patient charter to define the realistic and achievable principles of care that patients with CU should expect to receive. Principle (1): I deserve an accurate and timely diagnosis of my CU; Principle (2): I deserve access to specialty care for my CU; Principle (3): I deserve access to innovative treatments that reduce the burden of CU on my daily life; Principle (4): I deserve to be free of unnecessary treatment-related side-effects during the management of my CU; and Principle (5): I expect a holistic treatment approach to address all the components of my life impacted by CU. The stated principles may serve as a guide for healthcare providers who care for patients with CU and translate into better patient-physician communication. In addition, we urge policymakers and authors of CU treatment guidelines to consider these principles in their decision-making to ensure the goals of the patient are achievable.

Indexed as

AngioedemaChronic UrticariaDrug-Related Side Effects and Adverse ReactionsUrticariaChronic DiseaseHumansPatientsQuality of LifeAngioedemaChronic urticariaHealth careHivesPatient advocacyWheals

Identifiers

PMID37991694
PMCPMC10796664
OpenAlexW4388912340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.